A citation-based method for searching scientific literature

Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra Green, Afshin Salsali, Uli C Broedl, Hans J Woerle. Diabetes Care 2015
Times Cited: 253



Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull, Christopher P Cannon, George Capuano, Pei-Ling Chu, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, David C Wheeler, Yshai Yavin, Hong Zhang, Bernard Zinman, Gary Meininger, Barry M Brenner, Kenneth W Mahaffey. N Engl J Med 2019
Times Cited: 1180




List of shared articles



Times cited

Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
Mohammad Shafi Kuchay, Khalid Jamal Farooqui, Sunil Kumar Mishra, Ambrish Mithal. Adv Exp Med Biol 2021
3


Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.
Nan Ye, Meg J Jardine, Megumi Oshima, Carinna Hockham, Hiddo J L Heerspink, Rajiv Agarwal, George Bakris, Aletta E Schutte, Clare Arnott, Tara I Chang,[...]. Circulation 2021
2

Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome.
Muhammad Imtiaz Ahmad, Michael D Shapiro. Curr Atheroscler Rep 2021
0

Hypertension: Current trends and future perspectives.
Paul G Hunter, Fiona A Chapman, Neeraj Dhaun. Br J Clin Pharmacol 2021
0

Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.
Zhenghong Liu, Xiaoxuan Ma, Iqra Ilyas, Xueying Zheng, Sihui Luo, Peter J Little, Danielle Kamato, Amirhossein Sahebkar, Weiming Wu, Jianping Weng,[...]. Theranostics 2021
0



Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease.
Kazuomi Kario, Keith C Ferdinand, James H O'Keefe. Prog Cardiovasc Dis 2020
12

Using adult stem cells to monitor endothelial dysfunction in diabetes mellitus.
Rohit Jain, Hassan Awal, Sabyasachi Sen. J Diabetes Complications 2020
3

Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
Ona Kinduryte Schorling, Douglas Clark, Isabella Zwiener, Stefan Kaspers, Jisoo Lee, Hristo Iliev. Adv Ther 2020
2


The Evolving Understanding and Approach to Residual Cardiovascular Risk Management.
Devinder S Dhindsa, Pratik B Sandesara, Michael D Shapiro, Nathan D Wong. Front Cardiovasc Med 2020
7

Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo-Controlled Trial.
Anne Zanchi, Michel Burnier, Marie-Eve Muller, Arlène Ghajarzadeh-Wurzner, Marc Maillard, Nicolas Loncle, Bastien Milani, Nathalie Dufour, Olivier Bonny, Menno Pruijm. J Am Heart Assoc 2020
5

Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists.
C Berra, R Manfrini, D Regazzoli, M G Radaelli, O Disoteo, C Sommese, P Fiorina, G Ambrosio, F Folli. Pharmacol Res 2020
3

SGLT2 Inhibitors in Resistant Hypertension: A Sweet Solution.
Karen C Tran, Swapnil Hiremath. Am J Hypertens 2020
0

Sodium-Glucose Cotransporter-2 Inhibitor Immediately Decreases Serum Uric Acid Levels in Type 2 Diabetic Patients.
Naro Ohashi, Taro Aoki, Takashi Matsuyama, Sayaka Ishigaki, Shinsuke Isobe, Tomoyuki Fujikura, Takuya Hashimoto, Daisuke Tsuriya, Hiroshi Morita, Akihiko Kato,[...]. Med Sci Monit 2020
1

What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
Muhammad Shahzeb Khan, Muthiah Vaduganathan. Curr Diab Rep 2020
0

Effects of dapagliflozin on serum and urinary uric acid levels in patients with type 2 diabetes: a prospective pilot trial.
Tao Yuan, Shixuan Liu, Yingyue Dong, Yong Fu, Yan Tang, Weigang Zhao. Diabetol Metab Syndr 2020
1